Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Biodegradable nanoparticles" patented technology

Biodegradable nanoparticles (NPs) are colloidal particles with a gene of interest encapsulated inside a polymeric matrix. They are typically 100 nm in diameter, and are formulated using FDA-approved, biodegradable, biocompatible polymers such as poly(D,L-lactide-co-glycolide) (PLGA) or polylactide (PLA).

Radiopaque nanoparticles for medical imaging

ActiveUS12673121B2Liver imagingUrinary excretion
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Owner:TRANSLATIONAL & FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC

Nanoparticles for targeted elimination of intracellular bacteria and preparation method thereof

ActiveCN117065048BAntibacterial agentsNanomedicineBiodegradable nanoparticlesLinear polymer
The present invention provides nanoparticles for targeted elimination of intracellular bacteria and a preparation method thereof. The nanoparticles are composed of a biodegradable nanoparticle matrix, a potassium ion-responsive linear polymer grafted onto the surface of the nanoparticle matrix, and a drug loaded into the pore structure of the nanoparticle matrix. The nanoparticle matrix has a pore structure, the drug is a drug for treating bacterial infection, and the potassium ion-responsive linear polymer can achieve conformational transition and charge reversal after recognizing and responding to potassium ions. The nanoparticles are taken into the cells through the endocytosis of macrophages. In the high potassium ion concentration environment within the cells, the potassium ion-responsive linear polymer on the surface of the nanoparticles complexes with potassium ions, causing the nanoparticles, which are negatively charged in the extracellular fluid, to undergo charge reversal within the cells, thereby inducing the nanoparticles to target and bind to the intracellular bacteria, while simultaneously undergoing conformational transition and releasing the loaded drug.
Owner:SICHUAN UNIV

A topological cyclodextrin / chitosan composite membrane, its preparation method and application

This invention discloses a topologically oriented cyclodextrin / chitosan composite membrane, its preparation method, and its applications, belonging to the field of bio-based nanomaterials technology. Using α-cyclodextrin and polyethylene glycol (PEG) as raw materials, this invention prepares topologically oriented cyclodextrin-PEG "ring-slippery" nanoparticles (TNPs). TNPs, as green and biodegradable nanoparticles, fill the chitosan network matrix, enhancing hydrogen bonding interactions with chitosan molecules and improving the mechanical properties of the chitosan membrane. This method not only uses simple raw materials and is easy to implement, but also effectively improves the mechanical strength of the chitosan composite membrane, effectively overcoming the problem of poor mechanical strength in existing chitosan composite membranes, and providing a simple and effective approach for practical production.
Owner:JIANGSU JICUIT MEDICAL FOOD TECHNOLOGY CO LTD

Radiopaque nanoparticles for medical imaging

PCT designated stage expiredWO2025117950A1Powder deliveryIn-vivo testing preparationsLiver imagingUrinary excretion
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Owner:TRANSLATIONAL & FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC

Functionalized nanoparticle composition with 5-fluorouracil to improve anticancer efficacy

Functionalized nanoparticle composition comprising 5-fluorouracil for enhanced anticancer activity, the composition comprising: a. 5-Fluorouracil at a quantity of 10.00% w / w, configured as an active anticancer agent; b. Poly(lactic acid-co-glycolic acid) at a quantity of 60.00% wt / w, configured to encapsulate the 5-fluorouracil and form a biodegradable nanoparticle matrix; c. Polyethylene glycol (PEG-2000) in an amount of 10.00% (w / w) configured to functionalize the surface of the nanoparticles and improve stability and bioavailability; d. Chitosan at a quantity of 5.00% (wt / wt), configured to effect surface modification and improve cellular uptake and targeting accuracy; e. Polyvinyl alcohol in an amount of 3.00% wt / wt, configured as a stabilizing and emulsifying agent during nanoparticle formation; f. Tween 80 at a concentration of 2.00% w / w, configured to improve dispersion stability and control particle size; and g. Mannitol at a quantity of 10.00% w / w, configured as a cryoprotectant to enhance stability during lyophilization and storage; the composition offering improved drug incorporation efficiency, delayed drug release, improved bioavailability, and enhanced anticancer activity compared to non-functionalized formulations of 5-fluorouracil.
Owner:FATIMA SABIHA +2

Polymeric nanoparticle compositions for encapsulation and sustained release of protein therapeutics

ActiveUS12648916B2Peptide/protein ingredientsNanomedicineIonic polymerizationBiodegradable nanoparticles
Described are new biodegradable nanoparticle platforms for encapsulation and sustained release of protein therapeutics through a scalable and reproducible method. Specifically nanoparticles comprising a complex comprising a protein, or peptide, and a counter ion polymer are described.
Owner:JOHNS HOPKINS UNIVERSITY

Radiopaque nanoparticles for medical imaging

ActiveUS20250177577A1Powder deliveryX-ray constrast preparationsLiver imagingUrinary excretion
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Owner:TRANSLATIONAL & FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC

A bioprinted intervertebral disc tissue engineering scaffold based on organoids

The present invention provides a bio-printed intervertebral disc tissue engineering scaffold based on organoids, which belongs to the technical field of intervertebral disc tissue engineering scaffolds. It includes a shell, the shell is filled with intervertebral disc organoid microspheres, and the upper end of the shell is connected to a mounting block, an artificial bionic fiber ring, the artificial bionic fiber ring is arranged on the outside of the shell, and the artificial bionic fiber ring contains left-handed polylactic acid, hyaluronic acid HA, vascular endothelial growth factor, type I collagen, polycaprolactone PCL, collagen and nano-hydroxyapatite, wherein the vascular endothelial growth factor is encapsulated in biodegradable nanoparticles and uniformly dispersed in the fiber ring material. The present application increases the internal surface area of ​​the microchannel through a multi-level grid structure of microchannels with different diameters and directions, provides more contact points for the exchange of nutrients, oxygen and metabolic waste, and monitors the microchannel through an intelligent response system to reduce the possibility of blockage.
Owner:FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA